Financial Performance - The company reported total revenue of $460 million for the fiscal year ending December 31, 2025, representing a 15% year-over-year increase [1] - In Q4 2025, total revenue reached $128 million, reflecting a 17% increase compared to the same quarter last year [1] - Product revenue growth was primarily driven by increased sales of Dingo and Nuozaile, with Dingo's Q4 product revenue netting $10.7 million, a 225% increase from $3.3 million in the same period last year [1] - Nuozaile's Q4 product revenue was $16 million, up 45% from $11 million year-over-year [1] Research and Development - R&D expenses for Q4 2025 amounted to $61.6 million, an increase from $52.3 million in Q4 2024 [1] - Total R&D spending for the year was $221 million, down from $235 million in 2024, mainly due to cost reductions from strategic resource optimization [1] Operating Expenses - Selling, general, and administrative expenses for the full year 2025 were $278 million, a decrease from $299 million in 2024, attributed to the same strategic resource optimization [1] Business Development - The company is advancing a differentiated global pipeline, including multiple projects such as Zocilurtatugpelitecan (zoci), with plans to initiate three registration studies by the end of 2026 [2] - The operating loss for 2025 was $229 million, a reduction compared to the previous year, primarily due to faster growth in product revenue outpacing operating expenses and a shift from foreign exchange losses to gains [2] - Overall, the company is showing positive growth trends across various business areas, particularly in new product launches and market expansion [2]

Core Insights - The company reported a total revenue of $127.6 million for Q4 2025, representing a 17% year-over-year increase, and an annual total revenue of $460.2 million, up 15% year-over-year [1] - The net loss for Q4 2025 was approximately $50.4 million, narrowing by 38.29% year-over-year, while the annual net loss was about $175.5 million, a reduction of 31.73% year-over-year [1] - As of December 31, 2025, the company had total cash, cash equivalents, short-term investments, and restricted cash amounting to $789.6 million [1] Revenue and R&D Expenditure - Q4 2025 product revenue netted $127.1 million, a 17% increase from $108.5 million in Q4 2024, and the annual product revenue netted $457.2 million, up 15% from $397.6 million in 2024 [1] - The R&D expenditure for Q4 2025 was $61.6 million, compared to $52.3 million in Q4 2024, while the annual R&D expenditure was $220.9 million, down from $234.5 million in 2024 [1] Strategic Developments - The reduction in net loss was attributed to product revenue growth outpacing operating expenses and a shift from foreign exchange losses to gains, although offset by decreased interest income [2] - The company plans to commercialize KarXT in the first half of 2026 and is actively developing targeted commercialization strategies and real-world evidence generation [2] - The CEO highlighted significant progress in the global innovation pipeline and emphasized the importance of executing around key catalysts in 2026 to prepare for future commercial growth [2]